Webcast

NeuroScienfitic Biopharmaceuticals Investor Briefing – 10 June

June 10, 2020

NeuroScienfitic Biopharmaceuticals Investor Briefing – 10 June

NeuroScienfitic Biopharmaceuticals (ASX: NSB) Webcast Replay

NeuroScienfitic Biopharmaceuticals Ltd (ASX: NSB) is a drug development company focused on developing novel peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need.

As a part of our ‘Meet the CEOs’ series, CEO Matthew Liddelow provides valuable insights to the company, its key markets and industry, and future prospects.

Recorded on 10th June 2020 at 12pm (AEST).

Join the next Meet the CEOs webcast

Speak to our Advisor team about this company

FEATURE SPEAKERS

Matthew Liddelow

CEO & Managing Director

NeuroScienfitic Biopharmaceuticals Ltd (ASX: NSB) is a drug development company focused on developing novel peptide-based pharmaceutical drugs for the treatment of neurodegenerative conditions with high unmet medical need. NSB’s lead drug candidate, called EmtinB, is currently being developed as a treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. EmtinB is in the advanced preclinicalphase of development with clinical development set to start by the end of 2020.

Speak to our Advisor team about this company



By clicking submit, I agree to the terms of the Reach Markets Financial Services Guide that includes the Privacy Statement.